Mindray Medical announces substantial yuan dividend, Q3 international business growth

Shenzhen Mindray Bio-Medical Electronics announced a cash dividend of 13.50 yuan (inclusive of tax) per 10 shares, totaling 1.64 bn yuan (inclusive of tax). This is based on a total share capital of 1,212,441,394 shares as of September 30, 2025. This decision, approved by the board of directors on October 28, 2025, falls within the authorization granted by the 2024 annual general meeting. The cumulative cash dividends for 2025, including previous distributions, amount to 4.93 bn yuan (inclusive of tax), representing 65.19% of the net profit for the first three quarters of 2025.

For the first three quarters of 2025, Mindray Medical reported total operating revenue of 25.83 bn yuan, a decrease of 12.38% year-over-year. However, the third quarter alone saw operating revenue of 9.09 bn yuan, marking a 1.53% increase compared to the same period last year. Net profit attributable to shareholders was 7.57 bn yuan, down 28.83% year-over-year.

International business grew by 11.93% in Q3, with notable strength in Europe (over 20% growth) and the CIS & Middle East/Africa regions (double-digit growth). R&D investment for the first three quarters was 268.64 m yuan, accounting for 10.40% of operating revenue. The company also continues to expand its product portfolio, holding 12,513 patent applications.